Abstract
Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.
MeSH terms
-
Adolescent
-
Adult
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / blood
-
Antifungal Agents / pharmacokinetics*
-
Area Under Curve
-
Carbamates / administration & dosage
-
Carbamates / blood
-
Carbamates / pharmacokinetics*
-
Drug Interactions
-
Drug Therapy, Combination
-
Female
-
Furans
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / blood
-
HIV Protease Inhibitors / pharmacokinetics*
-
Humans
-
Ketoconazole / administration & dosage
-
Ketoconazole / blood
-
Ketoconazole / pharmacokinetics*
-
Male
-
Middle Aged
-
Organophosphates / administration & dosage
-
Organophosphates / blood
-
Organophosphates / pharmacokinetics
-
Ritonavir / administration & dosage
-
Ritonavir / blood
-
Ritonavir / pharmacokinetics*
-
Sulfonamides / administration & dosage
-
Sulfonamides / blood
-
Sulfonamides / pharmacokinetics*
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Carbamates
-
Furans
-
HIV Protease Inhibitors
-
Organophosphates
-
Sulfonamides
-
amprenavir
-
Ritonavir
-
Ketoconazole
-
fosamprenavir